Axovant Gene Therapies, a clinical-stage company developing gene therapies, has signed a strategic partnership with Yposkesi, a contract development and manufacturing organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance. The ongoing prioritized access for manufacturing resou...